Fiche publication
Date publication
octobre 2024
Journal
Future medicinal chemistry
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MORJANI Hamid
Tous les auteurs :
Bimoussa A, Oubella A, Alossaimi MA, Aziz M, Attaullah HM, Ejaz SA, Morjani H, Auhmani A, Robert A, Riahi A, Riadi Y, Ait Itto MY
Lien Pubmed
Résumé
A series of (R)-Carvone-based 1,2,3-triazole-thiazolidinone hybrids were synthesized and characterized by spectroscopic techniques NMR and HRMS. The chemical reactivity and the stability parameters were observed via DFT. The objective was to evaluate the anticancer activity of the synthesized compounds against cancer cell lines. The mechanism of action by which the and exert their effect suggested that they may induce apoptosis through activation of caspase-3/7. This effect was observed against the most important NIMA-related kinases via Docking investigation. The designed compounds were identified as the best inhibitors of the NEK family via the inactivation of the caspase-3. The Docking results were supported by Dynamics where the binding energies justified the medicinal importance of the synthesized derivatives.
Mots clés
Bis-1,2,3-triazole, apoptosis, copper (II)-catalyzed, in vitro cytotoxic, molecular docking, molecular dynamic
Référence
Future Med Chem. 2024 10 10;:1-18
